Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes
Zainali Chunawala(Southwestern Medical Center), Ambarish Pandey(The University of Texas Southwestern Medical Center), Deepak L. Bhatt(Mount Sinai Hospital), Antoni Bayés‐Genís(Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Rodica Pop‐Busui(University of Michigan), Javed Butler(Jackson Memorial Hospital), Kershaw V. Patel(Houston Methodist), Alain G. Bertoni(Wake Forest University), Mark A. Espeland(Wake Forest University), Subodh Verma(St. Michael's Hospital), Carolyn Lam(National University of Singapore), Katelyn R Garcia(Wake Forest University), James L. Januzzi(Harvard University), Matthew W. Segar(Unknown)
Cited by 1
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k